10-Q: PepGen Inc. Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

PepGen Inc. released its third quarter 2024 financial results, highlighting progress in clinical trials for its lead product candidates and providing updates on its financial position.

Summary

• PepGen Inc., a clinical-stage biotechnology company, reported a net loss of $67.7 million for the nine months ended September 30, 2024, compared to a net loss of $59.1 million for the same period in 2023.
• Research and development expenses increased to $57.5 million for the nine months ended September 30, 2024, up from $51.8 million in the prior year period, driven by the advancement of clinical trials.
• General and administrative expenses also increased to $15.9 million for the nine months ended September 30, 2024, compared to $12.1 million in the prior year period, primarily due to increased personnel costs.
• The company's cash, cash equivalents, and marketable securities totaled $138.9 million as of September 30, 2024.
• PepGen believes its current financial resources will be sufficient to fund operations into 2026.
• The company completed a follow-on offering in February 2024, resulting in net proceeds of $76.4 million.
• PepGen is advancing two Phase 2 clinical trials for PGN-EDO51 and a Phase 1 and Phase 2 clinical trial for PGN-EDODM1.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is positive progress in clinical trials and a strong cash position, the increasing losses and reliance on future funding create some uncertainty. The company is making progress but faces significant challenges.

Positives

• The company has a strong cash position of $138.9 million, which is expected to fund operations into 2026.
• Initial clinical data for PGN-EDO51 shows promising results in exon skipping and dystrophin production.
• The company has received key regulatory designations for both PGN-EDO51 and PGN-EDODM1.
• Clinical trials for both lead product candidates are progressing with patient dosing underway.
• The company has successfully raised additional capital through a follow-on offering.

Negatives

• The company has incurred significant operating losses, with a net loss of $67.7 million for the nine months ended September 30, 2024.
• Research and development expenses have increased, reflecting the high costs of clinical trials.
• The company is still in the early stages of development and has not yet generated any revenue from product sales.
• The company is dependent on third parties for manufacturing and clinical testing.

Risks

• The company is early in its development efforts and may not be able to successfully advance product candidates through clinical trials.
• Clinical trials may not demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• The company relies on third parties for manufacturing and testing, which may not perform satisfactorily.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company may not be able to obtain and maintain patent protection for its technology.
• The company will need to raise substantial additional funding in the future.
• The price of the company's common stock is volatile and may fluctuate substantially.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2026. The company expects to continue to incur significant expenses and operating losses as it advances its clinical programs and expands its operations.

Management Comments

• Based on the totality of data in both the 5 mg/kg cohort and the ongoing 10 mg/kg cohort in the CONNECT1 trial as of October 31, 2024, we believe PGN-EDO51 has a favorable emerging safety profile.
• Based on learnings from the 5 mg/kg cohort, we have amended the CONNECT1 study protocol.
• The CONNECT2 study, together with data from the CONNECT1 study, is intended to support a potential accelerated approval pathway for PGN-EDO51, subject to regulatory authority feedback.

Industry Context

The announcement reflects the ongoing efforts in the biotechnology industry to develop novel therapies for rare genetic diseases, particularly in the areas of neuromuscular and neurological disorders. The company is competing with other companies developing similar and different approaches to treating these diseases.

Comparison to Industry Standards

• The reported exon skipping levels of 2.15% in the CONNECT1 study are compared to publicly available data for other DMD exon 51-skipping approaches, suggesting a competitive profile.
• The company's approach to DM1 treatment is described as unique, indicating a differentiation from other approaches in more advanced stages of clinical development.
• The company's use of peptide-conjugated oligonucleotides is a novel approach, and the safety profile is being closely monitored in comparison to other oligonucleotide therapeutics.
• The company is competing with companies such as Sarepta, Dyne, BioMarin, and Vertex, all of which are developing therapies for DMD and DM1.

Management Changes

Legal Proceedings

• The company is not party to any material legal proceedings.

Related Party Transactions

• The company has a Technology License Agreement with Oxford University Innovation Limited, or OUI.
• Entities affiliated with RA Capital Management, L.P., or RA Capital, purchased common stock in the Companys IPO and Follow-on Offering.
• Two members of the Companys board of directors, Dr. Joshua Resnick and Habib Dable, are affiliated with RA Capital.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the progress of its clinical programs.
• Employees are impacted by the company's growth and the need to hire additional personnel.
• Patients with DMD and DM1 are impacted by the potential development of new therapies.
• Suppliers and manufacturers are impacted by the company's reliance on third parties for manufacturing and testing.
• Creditors are impacted by the company's financial position and its ability to raise additional capital.

Next Steps

• The company plans to continue to engage with regulators in the European Union regarding the CONNECT2 study.
• The company expects to file an investigational new drug application and open the CONNECT2 clinical trial in the U.S. by year-end, subject to regulatory clearance.
• The company expects to report data from both the 5 mg/kg and 10 mg/kg dose cohorts in the FREEDOM study by the end of the first quarter of 2025.
• The company expects to initiate patient dosing in the FREEDOM2 study in the fourth quarter of 2024.
• The company also plans to open the FREEDOM2 study in the U.S., subject to regulatory clearance.
• The company continues to evaluate PGN-EDO53 in CTA and/or IND-enabling preclinical studies.

Key Dates

Keywords

Oligonucleotide Therapeutics, Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1, Clinical Trials, Exon Skipping, Dystrophin, Biotechnology, Rare Diseases, Neuromuscular Diseases, PGN-EDO51, PGN-EDODM1, EDO Platform